A recent study highlighted the barriers to hepatitis C virus (HCV) direct‐acting antiviral therapy among individuals coinfected with HIV and HCV. The barriers included select antiretroviral regimens, substance use, and kidney disease. Have you experienced barriers to your patients receiving HCV direct‐acting antiviral therapy?